Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul 23;50(3):36-46.

Assesment of Risk Factors for Tardive Dyskinesia

Affiliations

Assesment of Risk Factors for Tardive Dyskinesia

Melek Kanarya Vardar et al. Psychopharmacol Bull. .

Abstract

Objective: Aim of the study is to evaluate sociodemographic and clinical features that may be associated with the development of Tardive dyskinesia (TD).

Methods: 80 patients attending an outpatient psychiatry clinic in Istanbul, Turkey were divided into TD (n = 50) and control groups (CG) (n = 30). Sociodemographic and clinical data was collected through face-to-face interviews and a retrospective search of medical records.

Results: There was a significant difference between TD and control group (CG) in terms of mean; onset of psychiatric disease at or after 35 years of age; first use of APD at or after 35 years of age; use of long-acting injectable APD; history of extrapyramidal side-effects; history of akathisia and family history of psychiatric disease. There was no significant difference between the two groups in terms of DSM- IV-based psychiatric diagnosis distributions, the existence of complete recovery periods during the course of the disease; total duration of APD use for at least 10 years; APD holidays; regular APD use; history of ECT and smoking or alcohol and substance abuse/addiction.

Conclusion: Advancing age seemed to be the most significant risk factor in the development of TD. Clinicians need to be cautious about TD when prescribing APD for elderly patients.

Keywords: Tardive dyskinesia; antipsychotic drugs; drug-induced movement disorders.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest The authors have no conflicts of interest

Similar articles

Cited by

References

    1. Carbon M, Hsieh CH, Kane JM, Correll CU. Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: A Meta-Analysis. J Clinical Psychiatry. 2017;78(3):264–278. - PubMed
    1. Nalbant A, Can A, Burhan HS, Cansız A, Yavuz KF, Delice MA, et al. Tardive dyskinesia in long term hospitalized patients with schizophrenia. Dusunen Adam The Journal of Psychiatry and Neurological Sciences. 2016;29:259–265.
    1. Jeste DV, Caligiuri MP. Tardive dyskinesia. Schizophr Bull. 1993;119:303–315. - PubMed
    1. Achalia RM, Chaturvedi SK, Desai G, Rao GN, Prakash O. Prevalence and risk factors associated with tardive dyskinesia among Indian patients with schizophrenia. Asian J Psychiatr. 2014;9:31–35. - PubMed
    1. Woerner MG, Alvir JM, Saltz BL, Lieberman JA, Kane JA. Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am J Psychiatry. 1998;155(11):1521–1528. - PubMed

Substances

LinkOut - more resources